Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Assessing the benefit–risk profile of newer glucose‐lowering drugs: A systematic review and network meta‐analysis of randomized outcome trials

Diabetes Obesity and Metabolism(2024)10.1111/dom.16147Source: DataRank Database

Assessing the benefit–risk profile of newer glucose‐lowering drugs: A systematic review and network meta‐analysis of randomized outcome trials is a research paper published in Diabetes Obesity and Metabolism (2024). On theSindex it has a DataRank of 0. It has been cited 12 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access12 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)OA: bronzeTopics (15)IDs (PubMed, PMC)Annotations (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (14)

Bingyu Zhang ORCID,Yiwen Lu ORCID,William T. Donahoo ORCID,Naykky Singh Ospina ORCID,Pareeta Kotecha ORCID

Live enrichment

PubMed:39723481 PMC:PMC12135018

Division of Diabetes, Endocrinology, and Metabolic Diseases

Grant: R01DK133465

NCI NIH HHS

Grant: K08 CA248972

bronzeLicense: http://doi.wiley.com/10.1002/tdm_license_1.1

publisherhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.16147

publisherhttps://dom-pubs.pericles-prod.literatumonline.com/doi/pdf/10.1111/dom.16147

publisherhttps://dom-pubs.pericles-prod.literatumonline.com/doi/full-xml/10.1111/dom.16147

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC12135018/

MeSH Terms

HumansCardiovascular DiseasesDiabetes Mellitus, Type 2Blood GlucoseHypoglycemic AgentsRisk AssessmentRandomized Controlled Trials as TopicDipeptidyl-Peptidase IV InhibitorsSodium-Glucose Transporter 2 InhibitorsGlucagon-Like Peptide-1 Receptor Agonists

Keywords

Type 2 diabetesSglt2 InhibitorMeta‐analysisDpp‐iv InhibitorGlp‐1 Analogue